| Literature DB >> 18483573 |
Abstract
Different hexoprenaline (Hx(2)SO(4)) conventional and coated wire electrodes were constructed and evaluated. Membranes were based on hexoprenalinium phosphotungstate (Hx-PTA) and hexporenalinium phosphomolybdate (Hx-PMA). The electrodes were fully characterized in terms of their composition, response time, life span, pH, and temperature and then were applied to the potentiometric determination of the hexoprenalinium ion in its pure state, pharmaceutical preparations, and biological samples, urine and plasma, under batch and flow injection conditions. The selectivity of the electrodes towards many inorganic cations, sugars, amino acids, and some other brochodilatures of close chemical composition was also tested.Entities:
Year: 2008 PMID: 18483573 PMCID: PMC2375976 DOI: 10.1155/2008/586310
Source DB: PubMed Journal: J Autom Methods Manag Chem ISSN: 1463-9246
Figure 1Schematic diagram of the flow injection system used in measurements.
Response characteristics of the electrodes under investigation.
| Electrode | Min Presoak time (h) | Slope mV/concentration decade | Response time (s) | Lifespan |
|---|---|---|---|---|
| Hx-PTA conventional (I) | 1/2 | 58.7 | 30 | 8 weeks |
| Hx-PTA graphite (II) | 1.0 | 57.3 | 25 | 2 weeks |
| Hx-PTA Copper (III) | 1.0 | 57.0 | 20 | 10 days |
| Hx-PTA Silver (IV) | 1.5 | 56.4 | 20 | 7 days |
| Hx-PTA Platinum (V) | 1.5 | 55.0 | 20 | 48 hours |
| Hx-PMA Conventional (I) | 1.0 | 59.3 | 30 | 9 weeks |
| Hx-PMA graphite (II) | 2.0 | 58.5 | 25 | 12 days |
| Hx-PMA Copper (III) | 1.5 | 58.0 | 20 | 11 days |
| Hx-PMA Silver (IV) | 1.5 | 55.4 | 20 | 7 days |
| Hx-PMA Platinum (V) | 1.5 | 55.0 | 20 | 48 hrs |
Figure 2Variation of E° of Hx-PTA (a) and Hx-PMA (b) graphite electrodes with temperature.
Variation of the slopes of the calibration graphs (mV/concentration decade) with flow rate.
| Flow rate | 4.15 | 5.35 | 7.50 | 9.70 | 12.50 | 17.85 | 23.25 | 25.00 | 27.00 | 30.00 |
|---|---|---|---|---|---|---|---|---|---|---|
| Electrode | Slope (mV/ concentration decade) | |||||||||
| Hx-PTA (I) | 63.1 | 64.5 | 68.2 | 69.7 | 72.4 | 75.4 | 75.9 | 76.3 | 77.0 | |
| Hx-PTA (II) | 61.0 | 62.7 | 64.5 | 66.8 | 68.2 | 69.6 | 70.4 | 71.2 | 72.6 | |
| Hx-PTA (III) | 62.5 | 64.9 | 65.8 | 66.3 | 67.2 | 68.4 | 69.3 | 70.3 | 71.2 | |
| Hx-PTA (IV) | 61.5 | 63.5 | 64.9 | 66.7 | 67.3 | 68.2 | 69.0 | 69.2 | 70.3 | |
| Hx-PTA (V) | 63.3 | 66.2 | 67.5 | 68.3 | 69.7 | 70.4 | 71.2 | 71.9 | 72.3 | |
| Hx-PTA (I) | 59.7 | 60.4 | 63.0 | 64.7 | 66.2 | 67.1 | 67.8 | 68.0 | 69.3 | |
| Hx-PTA (II) | 61.4 | 64.5 | 65.7 | 67.1 | 68.4 | 69.5 | 69.8 | 70.2 | 70.7 | |
| Hx-PTA (III) | 62.5 | 64.6 | 65.9 | 67.2 | 68.3 | 69.8 | 70.3 | 70.9 | 70.6 | |
| Hx-PTA (IV) | 61.3 | 63.5 | 65.0 | 66.2 | 67.8 | 68.9 | 70.4 | 71.5 | 73.0 | |
| Hx-PTA (V) | 62.0 | 63.9 | 65.7 | 66.8 | 68.1 | 69.2 | 70.3 | 70.9 | 71.6 | |
*Slop at flow rate selected as optimum working condition.
Figure 3Recordings obtained for hexoprenaline solution having pHx = 5.5–2.0 using Hx-PTA conventional electrode at optimum FIA conditions.
Figure 4Effect of pH of the test solution of concentration 1 × 10−3 M hexoprenaline on the potential response of a-Hx-PTA(I), b-Hx-PTA(II), c-Hx-PTA(III), d-HX-PTA(IV), and e-Hx-PTA(V) electrodes at optimum FIA conditions.
Selectivity coefficients and tolerance values for the Hx conventional-type electrodes.
| Hx-PTA | Hx-PMA | |||||
|---|---|---|---|---|---|---|
| Batch | FIA | Batch | FIA | |||
| Interferent | SSM* | MSM** | SSM* | MSM** | ||
| Na+ | 3.42 | 4.62 | 5.23 | 3.18 | 4.35 | 4.98 |
| K+ | 2.98 | 3.68 | 5.75 | 3.34 | 4.82 | 5.32 |
| Mg2+ | 4.75 | — | 6.21 | 5.45 | — | 6.74 |
| Ca2+ | 5.32 | — | 5.98 | 5.87 | — | 6.48 |
| Cr3+ | 3.89 | — | 4.96 | 4.62 | — | 6.08 |
| Fe3+ | 4.21 | — | 5.66 | 4.51 | — | 6.14 |
| Al3+ | 6.83 | — | 7.55 | 5.29 | — | 6.59 |
| Theronine | — | 5.95 | 8.20 | — | 5.74 | 6.79 |
| Leucine | — | 5.45 | 8.97 | — | 6.32 | 7.86 |
| Valine | — | 7.62 | 9.32 | — | 5.87 | 7.36 |
| Glycine | — | 5.96 | 6.87 | — | 6.35 | 9.42 |
| Alanine | — | 8.62 | 10.75 | — | 7.44 | 9.87 |
| Salbutamol | — | 7.65 | 10.94 | — | 5.98 | 10.24 |
| Orciprenaline | — | 6.85 | 10.44 | — | 6.47 | 10.53 |
| Terbutiline | — | 6.77 | 9.87 | — | 6.85 | 10.42 |
| Urea | — | 6.50 | 8.09 | — | 7.12 | 10.88 |
| Lactose | — | 4.98 | 6.42 | — | 4.68 | 7.82 |
| Glucose | — | 4.63 | 7.01 | — | 4.79 | 6.89 |
| Maltose | — | 5.01 | 6.85 | — | 5.13 | 8.44 |
| Fructose | — | 5.23 | 7.35 | — | 5.58 | 7.96 |
| Saccharose | — | 4.99 | 7.12 | — | 5.62 | 8.90 |
| Gum xanthine | — | 6.32 | 7.93 | — | 5.78 | 7.38 |
*SSM: separate solution method.
**MSM: mixed solution method.
Determination of hexoprenaline employing the different Hx-PTA electrodes applying the standard additions method under batch conditions.
| Hx-PTA (I) | Hx-PTA (II) | Hx-PTA (III) | Hx-PTA (IV) | Hx-PTA (V) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sample | Taken | Recovery | RSD(b) | Recovery | RSD(b) | Recovery | RSD(b) | Recovery | RSD(b) | Recovery | RSD(b) |
| (a)/mg | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | |
| Pure solutions | 5.186 | 98.7 | 0.19 | 99.5 | 0.15 | 99.7 | 0.25 | 99.2 | 0.39 | 98.7 | 0.24 |
| 51.860 | 99.5 | 0.15 | 99.7 | 0.21 | 99.4 | 0.29 | 98.6 | 0.24 | 98.3 | 0.35 | |
| 518.60 | 99.8 | 0.19 | 100.2 | 0.35 | 99.9 | 0.31 | 99.5 | 0.35 | 99.0 | 0.18 | |
| Asmadol® | 5.186 | 98.8 | 0.09 | 98.5 | 0.30 | 97.8 | 0.24 | 99.6 | 0.28 | 100.0 | 0.31 |
| 51.860 | 100.2 | 0.36 | 99.3 | 0.19 | 98.4 | 0.19 | 100.0 | 0.44 | 100.6 | 0.46 | |
| 518.60 | 101.4 | 0.24 | 99.9 | 0.28 | 99.3 | 0.35 | 100.5 | 0.37 | 101.6 | 0.52 | |
| Gynipral® | 5.186 | 98.5 | 0.18 | 99.2 | 0.37 | 98.6 | 0.41 | 100.1 | 0.19 | 99.6 | 0.22 |
| 51.860 | 100.5 | 0.16 | 100.1 | 0.19 | 99.8 | 0.33 | 99.8 | 0.25 | 98.8 | 0.36 | |
| 518.60 | 99.9 | 0.21 | 100.9 | 0.26 | 100.4 | 0.27 | 99.4 | 0.42 | 100.4 | 0.48 | |
| Urine | 5.186 | 97.5 | 0.15 | 100.0 | 0.37 | 100.2 | 0.22 | 99.6 | 0.17 | 98.9 | 0.21 |
| 51.860 | 98.6 | 0.19 | 100.6 | 0.42 | 100.1 | 0.34 | 100.2 | 0.26 | 97.6 | 0.38 | |
| 518.60 | 99.8 | 0.23 | 101.2 | 0.36 | 101.6 | 0.16 | 101.5 | 0.37 | 99.4 | 0.29 | |
| Plasma | 5.186 | 98.0 | 0.41 | 99.3 | 0.29 | 98.6 | 0.33 | 99.4 | 0.36 | 97.5 | 0.36 |
| 51.860 | 98.6 | 0.25 | 98.7 | 0.17 | 99.2 | 0.24 | 98.5 | 0.45 | 98.3 | 0.45 | |
| 518.60 | 98.8 | 0.22 | 99.6 | 0.23 | 100.4 | 0.44 | 97.3 | 0.38 | 98.6 | 0.40 | |
(a)Taken mg per 50 mL.
(b)Five determinations.
Determination of hexoprenaline in plasma and urine employing the different Hx-PTA and Hx-PMA electrodes under FIA conditions.
| Urine | Plasma | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Taken | 5.186 mg | 51.860 mg | 518.600 mg | 5.186 mg | 51.860 mg | 518.600 mg | ||||||
| Recovery* | A | B | A | B | A | B | A | B | A | B | A | B |
| Hx-PTA (I) | 85.3 | 98.2 | 88.6 | 99.5 | 90.5 | 100.4 | 84.6 | 99.7 | 87.6 | 100.2 | 95.4 | 100.8 |
| Hx-PTA (II) | 84.1 | 98.3 | 89.1 | 100.3 | 92.3 | 100.7 | 85.2 | 98.5 | 86.9 | 101.4 | 96.8 | 99.7 |
| Hx-PTA (III) | 83.7 | 98.7 | 88.2 | 98.9 | 94.3 | 101.2 | 83.2 | 100.8 | 88.9 | 100.5 | 97.0 | 102.6 |
| Hx-PTA (IV) | 84.2 | 99.2 | 89.4 | 100.5 | 95.4 | 99.9 | 83.9 | 100.0 | 90.1 | 100.9 | 95.5 | 101.5 |
| Hx-PTA (V) | 85.4 | 98.4 | 92.3 | 101.2 | 93.8 | 98.9 | 84.7 | 101.2 | 95.4 | 100.4 | 92.8 | 100.7 |
| Hx-PMA (I) | 86.3 | 99.9 | 90.1 | 100.3 | 96.2 | 100.2 | 83.9 | 100.7 | 93.1 | 99.9 | 97.4 | 99.6 |
| Hx-PMA (II) | 83.7 | 100.2 | 89.9 | 98.6 | 94.7 | 99.6 | 86.1 | 99.6 | 89.8 | 100.1 | 96.1 | 98.9 |
| Hx-PMA (III) | 84.6 | 100.5 | 93.2 | 100.8 | 93.8 | 101.3 | 88.6 | 98.5 | 90.7 | 99.8 | 95.4 | 100.0 |
| Hx-PMA (IV) | 88.0 | 98.6 | 91.6 | 102.1 | 96.5 | 100.5 | 85.9 | 100.4 | 92.3 | 101.3 | 93.8 | 101.4 |
| Hx-PMA (V) | 86.9 | 99.3 | 90.4 | 101.3 | 97.0 | 100.2 | 86.2 | 100.9 | 94.3 | 100.2 | 95.3 | 100.6 |
A: recovery at optimum flow rate (7.50 mL/min for conventional electrodes, 5.35 mL/min for coated wire electrodes).
B: recovery at flow rate 2.50 mL/min.
*Average of three determinations.
Statistical treatment of data obtained for the determination of Hexoprenaline using Hx conventional electrodes in comparison with the official method.
| Hx-PTA | Hx-PMA | |||
|---|---|---|---|---|
| Batch | FIA | Batch | FIA | |
| Pure solutions | ||||
| X ± S.E.* | 100.23 ± 0.85 | 99.85 ± 0.74 | 99.80 ± 0.93 | 101.27 ± 0.21 |
| Relative error (%) | 0.13 | 0.15 | 0.07 | 0.22 |
| 2.56 | 2.98 | 3.45 | 4.21 | |
| Slope of regression line | 0.998 | 0.986 | 0.995 | 0.978 |
| Intercept of regression line | −0.087 | −0.073 | 0.045 | −0.062 |
| Asmadol® | ||||
| X ± S.E.* | 100.54 ± 0.23 | 100.75 ± 0.74 | 99.63 ± 0.44 | 100.82 ± 0.50 |
| Relative error (%) | 0.05 | 0.13 | 0.09 | 0.24 |
| 3.78 | 4.12 | 2.68 | 2.49 | |
| Slope of regression line | 0.999 | 0.988 | 0.986 | 0.993 |
| Intercept of reg. line | 0.012 | −0.023 | −0.031 | 0.009 |
| Gynipral® | ||||
| X ± S.E.* | 100.81 ± 0.34 | 100.25 ± 0.62 | 100.26 ± 0.48 | 101.2 ± 0.21 |
| Relative error (%) | 0.14 | 0.52 | 0.18 | 0.31 |
| 4.57 | 3.51 | 2.88 | 3.69 | |
| Slope of regression line | 0.992 | 0.989 | 0.996 | 0.985 |
| Intercept of regression line | −0.091 | 0.036 | 0.018 | 0.042 |
| Urine | ||||
| X ± S.E.* | 100.54 ± 0.41 | 99.48 ± 0.56 | 100.56 ± 0.45 | 100.12 ± 0.34 |
| Relative error (%) | 0.09 | 0.12 | 0.24 | 0.06 |
| 3.74 | 3.92 | 4.53 | 5.26 | |
| Slope of regression line | 0.991 | 0.984 | 0.975 | 0.994 |
| Intercept of regression line | 0.029 | −0.015 | −0.026 | −0.035 |
| Plasma | ||||
| X ± S.E.* | 100.2 ± 0.85 | 99.8 ± 0.74 | 99.8 ± 0.93 | 100.36 ± 0.54 |
| Relative error (%) | 0.18 | 0.14 | 0.25 | 0.32 |
| 2.87 | 3.19 | 3.57 | 2.96 | |
| Slope of regression line | 0.999 | 0.978 | 0.982 | 0.990 |
| Intercept of regression line | −0.014 | −0.026 | 0.034 | 0.091 |
X ± S.E.*: average ± standard error.
**One tailed critical F-value.
N.B.: for the official method (X ± S.E.) = 100.8 ± 0.65.